This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-145-5p | APH1A | -2.62 | 0 | 0.59 | 0 | miRNAWalker2 validate | -0.15 | 0 | NA | |
2 | hsa-miR-330-3p | CREBBP | 1.76 | 0 | -0.59 | 0 | MirTarget; PITA; miRNATAP | -0.11 | 2.0E-5 | NA | |
3 | hsa-miR-330-5p | CREBBP | 2.22 | 0 | -0.59 | 0 | miRanda | -0.13 | 0 | NA | |
4 | hsa-miR-103a-3p | DLL1 | 1.51 | 0 | -1.56 | 0 | miRNATAP | -0.45 | 0 | NA | |
5 | hsa-miR-107 | DLL1 | 1.81 | 0 | -1.56 | 0 | PITA; miRanda; miRNATAP | -0.45 | 0 | NA | |
6 | hsa-miR-130b-3p | DLL1 | 3.42 | 0 | -1.56 | 0 | miRNATAP | -0.23 | 0 | NA | |
7 | hsa-miR-142-3p | DLL1 | 2.07 | 0 | -1.56 | 0 | miRanda | -0.16 | 0.00012 | NA | |
8 | hsa-miR-146b-5p | DLL1 | 1.31 | 0 | -1.56 | 0 | miRanda | -0.24 | 1.0E-5 | NA | |
9 | hsa-miR-15a-5p | DLL1 | 1.78 | 0 | -1.56 | 0 | miRNATAP | -0.43 | 0 | NA | |
10 | hsa-miR-15b-5p | DLL1 | 2.5 | 0 | -1.56 | 0 | miRNATAP | -0.41 | 0 | NA | |
11 | hsa-miR-16-5p | DLL1 | 1.88 | 0 | -1.56 | 0 | miRNATAP | -0.32 | 0 | NA | |
12 | hsa-miR-193a-3p | DLL1 | 0.42 | 0.05317 | -1.56 | 0 | miRanda | -0.2 | 0.00019 | NA | |
13 | hsa-miR-24-3p | DLL1 | 0.86 | 0 | -1.56 | 0 | miRNATAP | -0.23 | 0.00282 | NA | |
14 | hsa-miR-301a-3p | DLL1 | 1.94 | 0 | -1.56 | 0 | miRNATAP | -0.21 | 6.0E-5 | NA | |
15 | hsa-miR-320b | DLL1 | 1.1 | 0 | -1.56 | 0 | miRanda | -0.15 | 0.00549 | NA | |
16 | hsa-miR-326 | DLL1 | 1.07 | 6.0E-5 | -1.56 | 0 | miRanda | -0.15 | 0.0006 | NA | |
17 | hsa-miR-330-5p | DLL1 | 2.22 | 0 | -1.56 | 0 | miRanda | -0.3 | 0 | NA | |
18 | hsa-miR-34a-5p | DLL1 | 0.94 | 1.0E-5 | -1.56 | 0 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.15 | 0.00402 | 22438124 | Delta tocotrienol suppresses Notch 1 pathway by upregulating miR 34a in nonsmall cell lung cancer cells |
19 | hsa-miR-362-3p | DLL1 | 0.54 | 0.00242 | -1.56 | 0 | miRanda | -0.13 | 0.04186 | NA | |
20 | hsa-miR-362-5p | DLL1 | 0.45 | 0.02925 | -1.56 | 0 | PITA; TargetScan; miRNATAP | -0.14 | 0.0137 | NA | |
21 | hsa-miR-423-3p | DLL1 | 1.7 | 0 | -1.56 | 0 | PITA | -0.43 | 0 | NA | |
22 | hsa-miR-429 | DLL1 | 5.04 | 0 | -1.56 | 0 | miRanda; miRNATAP | -0.12 | 6.0E-5 | NA | |
23 | hsa-miR-454-3p | DLL1 | 1.53 | 0 | -1.56 | 0 | miRNATAP | -0.24 | 0.00028 | NA | |
24 | hsa-miR-486-5p | DLL1 | 0.63 | 0.03561 | -1.56 | 0 | miRanda | -0.12 | 0.0019 | NA | |
25 | hsa-miR-576-5p | DLL1 | 1.31 | 0 | -1.56 | 0 | PITA | -0.24 | 0.00014 | NA | |
26 | hsa-miR-589-5p | DLL1 | 1.56 | 0 | -1.56 | 0 | miRNATAP | -0.41 | 0 | NA | |
27 | hsa-miR-590-3p | DLL1 | 1.73 | 0 | -1.56 | 0 | PITA; miRanda; mirMAP | -0.27 | 0 | NA | |
28 | hsa-miR-15a-5p | DLL4 | 1.78 | 0 | -0.95 | 0 | miRNATAP | -0.27 | 0 | NA | |
29 | hsa-miR-15b-5p | DLL4 | 2.5 | 0 | -0.95 | 0 | miRNATAP | -0.28 | 0 | NA | |
30 | hsa-miR-16-5p | DLL4 | 1.88 | 0 | -0.95 | 0 | miRNATAP | -0.19 | 3.0E-5 | NA | |
31 | hsa-miR-30c-5p | DLL4 | 0.72 | 1.0E-5 | -0.95 | 0 | miRNATAP | -0.21 | 0 | NA | |
32 | hsa-miR-30d-5p | DLL4 | 0.58 | 0.00023 | -0.95 | 0 | miRNATAP | -0.17 | 0.00064 | NA | |
33 | hsa-miR-429 | DLL4 | 5.04 | 0 | -0.95 | 0 | miRanda | -0.13 | 0 | NA | |
34 | hsa-miR-484 | DLL4 | 2.63 | 0 | -0.95 | 0 | miRNATAP | -0.18 | 0 | NA | |
35 | hsa-miR-1254 | DTX1 | 2.69 | 0 | -0.47 | 0.0544 | miRNATAP | -0.13 | 0.00238 | NA | |
36 | hsa-miR-188-5p | DTX1 | 1.83 | 0 | -0.47 | 0.0544 | PITA | -0.11 | 0.02266 | NA | |
37 | hsa-miR-421 | DTX1 | 2.1 | 0 | -0.47 | 0.0544 | PITA; miRanda; miRNATAP | -0.11 | 0.03186 | NA | |
38 | hsa-miR-107 | DTX3 | 1.81 | 0 | -0.84 | 0 | miRanda | -0.16 | 0.0013 | NA | |
39 | hsa-miR-185-5p | DTX3 | 1.98 | 0 | -0.84 | 0 | MirTarget | -0.28 | 0 | NA | |
40 | hsa-miR-320a | DTX3L | 0.5 | 0.00226 | 0.46 | 0.00401 | miRanda | -0.11 | 0.02285 | NA | |
41 | hsa-miR-493-5p | DTX3L | 0.01 | 0.95887 | 0.46 | 0.00401 | MirTarget | -0.11 | 0.00011 | NA | |
42 | hsa-miR-495-3p | DTX3L | -1.05 | 0.00017 | 0.46 | 0.00401 | mirMAP | -0.1 | 0.0002 | NA | |
43 | hsa-miR-484 | DVL2 | 2.63 | 0 | -0.44 | 6.0E-5 | miRNAWalker2 validate | -0.1 | 5.0E-5 | NA | |
44 | hsa-let-7a-5p | DVL3 | 0.1 | 0.43289 | 0.26 | 0.00454 | TargetScan | -0.11 | 0.00261 | NA | |
45 | hsa-miR-106b-5p | EP300 | 2.18 | 0 | -0.21 | 0.12793 | miRNATAP | -0.14 | 5.0E-5 | NA | |
46 | hsa-miR-25-3p | EP300 | 1.36 | 0 | -0.21 | 0.12793 | miRNAWalker2 validate | -0.14 | 0.00108 | NA | |
47 | hsa-miR-26a-5p | EP300 | -0.63 | 0 | -0.21 | 0.12793 | miRNATAP | -0.14 | 0.01247 | NA | |
48 | hsa-miR-339-5p | EP300 | 1.79 | 0 | -0.21 | 0.12793 | miRanda | -0.1 | 0.00056 | NA | |
49 | hsa-miR-342-3p | EP300 | 0.91 | 0 | -0.21 | 0.12793 | MirTarget; PITA; miRanda; miRNATAP | -0.13 | 0.00146 | NA | |
50 | hsa-miR-361-3p | EP300 | 0.7 | 0 | -0.21 | 0.12793 | PITA | -0.13 | 0.00226 | NA | |
51 | hsa-miR-421 | EP300 | 2.1 | 0 | -0.21 | 0.12793 | miRanda | -0.11 | 0.00011 | NA | |
52 | hsa-miR-92a-3p | EP300 | 1.69 | 0 | -0.21 | 0.12793 | miRNAWalker2 validate | -0.13 | 0.00063 | NA | |
53 | hsa-let-7a-3p | HDAC2 | 1.03 | 0 | 0.47 | 7.0E-5 | mirMAP | -0.13 | 2.0E-5 | NA | |
54 | hsa-let-7b-3p | HDAC2 | 0.35 | 0.07056 | 0.47 | 7.0E-5 | mirMAP | -0.16 | 0 | NA | |
55 | hsa-miR-126-5p | HDAC2 | -0.59 | 3.0E-5 | 0.47 | 7.0E-5 | mirMAP | -0.16 | 6.0E-5 | NA | |
56 | hsa-miR-145-5p | HDAC2 | -2.62 | 0 | 0.47 | 7.0E-5 | miRNAWalker2 validate | -0.13 | 0 | 23499894 | MiR 145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer; Ectopic expression of miRNA mimics evidenced that miR-145 suppresses HDAC2 expression in HCC cells; In conclusion we suggest that loss or suppression of miR-145 may cause aberrant overexpression of HDAC2 and promote HCC tumorigenesis |
57 | hsa-miR-195-3p | HDAC2 | -1.78 | 0 | 0.47 | 7.0E-5 | mirMAP | -0.1 | 0 | NA | |
58 | hsa-miR-22-5p | HDAC2 | 1.63 | 0 | 0.47 | 7.0E-5 | mirMAP | -0.13 | 0 | NA | |
59 | hsa-miR-30a-3p | HDAC2 | 0.31 | 0.22984 | 0.47 | 7.0E-5 | mirMAP | -0.11 | 0 | NA | |
60 | hsa-miR-30b-5p | HDAC2 | 0.36 | 0.02886 | 0.47 | 7.0E-5 | mirMAP | -0.18 | 0 | NA | |
61 | hsa-miR-30c-5p | HDAC2 | 0.72 | 1.0E-5 | 0.47 | 7.0E-5 | mirMAP | -0.12 | 0.00034 | NA | |
62 | hsa-miR-30e-3p | HDAC2 | 0.12 | 0.34565 | 0.47 | 7.0E-5 | mirMAP | -0.18 | 2.0E-5 | NA | |
63 | hsa-miR-92a-3p | HES1 | 1.69 | 0 | 0.33 | 0.06313 | miRNAWalker2 validate | -0.17 | 0.00087 | NA | |
64 | hsa-miR-15b-5p | HES5 | 2.5 | 0 | 0.03 | 0.94494 | mirMAP | -0.28 | 0.00442 | NA | |
65 | hsa-miR-501-5p | HES5 | 1.63 | 0 | 0.03 | 0.94494 | PITA; miRNATAP | -0.2 | 0.02265 | NA | |
66 | hsa-miR-128-3p | JAG1 | 1.97 | 0 | -0.55 | 0.00271 | MirTarget | -0.26 | 0 | NA | |
67 | hsa-miR-146b-5p | JAG1 | 1.31 | 0 | -0.55 | 0.00271 | miRanda | -0.12 | 0.00349 | NA | |
68 | hsa-miR-16-1-3p | JAG1 | 2.09 | 0 | -0.55 | 0.00271 | MirTarget | -0.15 | 0.00014 | NA | |
69 | hsa-miR-186-5p | JAG1 | 1.01 | 0 | -0.55 | 0.00271 | MirTarget; miRNATAP | -0.25 | 6.0E-5 | NA | |
70 | hsa-miR-335-3p | JAG1 | 1.32 | 0 | -0.55 | 0.00271 | MirTarget | -0.17 | 2.0E-5 | NA | |
71 | hsa-miR-361-3p | JAG1 | 0.7 | 0 | -0.55 | 0.00271 | miRNATAP | -0.25 | 2.0E-5 | NA | |
72 | hsa-miR-590-5p | JAG1 | 1.46 | 0 | -0.55 | 0.00271 | MirTarget; PITA; miRanda; miRNATAP | -0.19 | 4.0E-5 | NA | |
73 | hsa-miR-93-3p | JAG1 | 2.62 | 0 | -0.55 | 0.00271 | MirTarget; miRNATAP | -0.1 | 0.00625 | NA | |
74 | hsa-miR-940 | JAG1 | 3.49 | 0 | -0.55 | 0.00271 | MirTarget; PITA; miRNATAP | -0.14 | 0 | NA | |
75 | hsa-miR-98-5p | JAG1 | 1.06 | 0 | -0.55 | 0.00271 | miRNAWalker2 validate | -0.22 | 0.00043 | NA | |
76 | hsa-miR-140-3p | JAG2 | -1.44 | 0 | 0.67 | 0.00018 | miRNATAP | -0.17 | 0.00075 | NA | |
77 | hsa-miR-106b-5p | KAT2B | 2.18 | 0 | -1.35 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.29 | 0 | NA | |
78 | hsa-miR-125a-3p | KAT2B | 0.77 | 6.0E-5 | -1.35 | 0 | miRanda | -0.16 | 0.00067 | NA | |
79 | hsa-miR-17-5p | KAT2B | 2.27 | 0 | -1.35 | 0 | MirTarget; TargetScan | -0.25 | 0 | 23095762 | miR 17 5p targets the p300/CBP associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells; Targeting of PCAF by miR-17-5p was evaluated using the luciferase reporter assay; Expression of PCAF in PCa cells was associated with the downregulation of miR-17-5p; Targeting of the 3'-untranslated region of PCAF mRNA by miR-17-5p caused translational suppression and RNA degradation and consequently modulation of AR transcriptional activity in PCa cells; PCAF is upregulated in cultured PCa cells and upregulation of PCAF is associated with the downregulation of miR-17-5p; Targeting of PCAF by miR-17-5p modulates AR transcriptional activity and cell growth in cultured PCa cells |
80 | hsa-miR-181a-5p | KAT2B | 0.97 | 0 | -1.35 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.13 | 0.00457 | NA | |
81 | hsa-miR-181b-5p | KAT2B | 1.3 | 0 | -1.35 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.2 | 2.0E-5 | NA | |
82 | hsa-miR-192-5p | KAT2B | 1.98 | 0 | -1.35 | 0 | miRNAWalker2 validate | -0.13 | 0.0001 | NA | |
83 | hsa-miR-19a-3p | KAT2B | 1.85 | 0 | -1.35 | 0 | miRNAWalker2 validate | -0.19 | 1.0E-5 | NA | |
84 | hsa-miR-19b-3p | KAT2B | 1.34 | 0 | -1.35 | 0 | miRNAWalker2 validate | -0.24 | 1.0E-5 | NA | |
85 | hsa-miR-20a-3p | KAT2B | 1.64 | 0 | -1.35 | 0 | MirTarget | -0.2 | 0 | NA | |
86 | hsa-miR-20a-5p | KAT2B | 1.51 | 0 | -1.35 | 0 | MirTarget | -0.14 | 0.00075 | NA | |
87 | hsa-miR-25-3p | KAT2B | 1.36 | 0 | -1.35 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.29 | 0 | NA | |
88 | hsa-miR-26b-5p | KAT2B | 0.3 | 0.04319 | -1.35 | 0 | miRNAWalker2 validate | -0.13 | 0.03161 | NA | |
89 | hsa-miR-29a-5p | KAT2B | -0.16 | 0.45228 | -1.35 | 0 | MirTarget | -0.1 | 0.0224 | NA | |
90 | hsa-miR-32-5p | KAT2B | 1.62 | 0 | -1.35 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.15 | 0.00313 | NA | |
91 | hsa-miR-429 | KAT2B | 5.04 | 0 | -1.35 | 0 | miRanda | -0.11 | 1.0E-5 | NA | |
92 | hsa-miR-590-3p | KAT2B | 1.73 | 0 | -1.35 | 0 | MirTarget; miRanda; mirMAP; miRNATAP | -0.11 | 0.02433 | NA | |
93 | hsa-miR-590-5p | KAT2B | 1.46 | 0 | -1.35 | 0 | miRanda | -0.14 | 0.00286 | NA | |
94 | hsa-miR-92a-3p | KAT2B | 1.69 | 0 | -1.35 | 0 | miRNAWalker2 validate; MirTarget | -0.27 | 0 | NA | |
95 | hsa-miR-93-5p | KAT2B | 2.58 | 0 | -1.35 | 0 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.2 | 0 | NA | |
96 | hsa-miR-129-5p | LFNG | -0.71 | 0.023 | 0.74 | 0.005 | MirTarget | -0.13 | 0.00109 | NA | |
97 | hsa-miR-146b-5p | LFNG | 1.31 | 0 | 0.74 | 0.005 | PITA; miRanda; miRNATAP | -0.16 | 0.00643 | NA | |
98 | hsa-miR-338-5p | LFNG | 0.59 | 0.04471 | 0.74 | 0.005 | PITA; miRNATAP | -0.15 | 0.00032 | NA | |
99 | hsa-miR-330-5p | MAML2 | 2.22 | 0 | -0.6 | 0.00855 | miRanda | -0.13 | 0.00774 | NA | |
100 | hsa-miR-421 | MAML2 | 2.1 | 0 | -0.6 | 0.00855 | miRanda | -0.13 | 0.00417 | NA | |
101 | hsa-miR-125a-3p | MAML3 | 0.77 | 6.0E-5 | -1.31 | 0 | miRanda | -0.16 | 0.00076 | NA | |
102 | hsa-miR-3065-3p | MAML3 | 2.26 | 0 | -1.31 | 0 | miRNATAP | -0.13 | 0 | NA | |
103 | hsa-miR-326 | MAML3 | 1.07 | 6.0E-5 | -1.31 | 0 | miRanda | -0.22 | 0 | NA | |
104 | hsa-miR-330-5p | MAML3 | 2.22 | 0 | -1.31 | 0 | miRanda | -0.4 | 0 | NA | |
105 | hsa-miR-339-5p | MAML3 | 1.79 | 0 | -1.31 | 0 | miRanda | -0.22 | 0 | NA | |
106 | hsa-miR-361-5p | MAML3 | 0.51 | 0.00011 | -1.31 | 0 | miRanda | -0.27 | 0.00011 | NA | |
107 | hsa-miR-421 | MAML3 | 2.1 | 0 | -1.31 | 0 | miRanda | -0.29 | 0 | NA | |
108 | hsa-miR-590-3p | MAML3 | 1.73 | 0 | -1.31 | 0 | miRanda | -0.26 | 0 | NA | |
109 | hsa-miR-590-3p | MFNG | 1.73 | 0 | -1.02 | 0 | miRanda | -0.11 | 0.02151 | NA | |
110 | hsa-miR-939-5p | MFNG | 2.15 | 0 | -1.02 | 0 | MirTarget | -0.19 | 0 | NA | |
111 | hsa-miR-30d-5p | NCOR2 | 0.58 | 0.00023 | -0.09 | 0.44858 | miRNATAP | -0.11 | 0.0019 | NA | |
112 | hsa-miR-140-5p | NCSTN | -0.89 | 0 | 0.88 | 0 | MirTarget; PITA; miRanda; miRNATAP | -0.14 | 6.0E-5 | NA | |
113 | hsa-miR-101-3p | NOTCH1 | -1.48 | 0 | 0.05 | 0.78359 | MirTarget | -0.12 | 0.01324 | NA | |
114 | hsa-miR-129-5p | NOTCH1 | -0.71 | 0.023 | 0.05 | 0.78359 | miRNAWalker2 validate | -0.11 | 1.0E-5 | NA | |
115 | hsa-miR-24-3p | NOTCH1 | 0.86 | 0 | 0.05 | 0.78359 | miRNAWalker2 validate; miRTarBase | -0.12 | 0.02474 | NA | |
116 | hsa-miR-30c-5p | NOTCH1 | 0.72 | 1.0E-5 | 0.05 | 0.78359 | miRNATAP | -0.1 | 0.03243 | 23974200 | We identified NOTCH1 as a direct target of miR-30c; Finally a block of miR-30c prevents C/EBPα-induced downregulation of Notch1 protein and leads to a reduced CD11b expression in myeloid differentiation; Our study presents the first evidence that C/EBPα miR-30c and Notch1 together play a critical role in granulocytic differentiation and AML and particularly in AML with CEBPA mutations |
117 | hsa-miR-30d-5p | NOTCH1 | 0.58 | 0.00023 | 0.05 | 0.78359 | miRNATAP | -0.15 | 0.0029 | NA | |
118 | hsa-miR-32-5p | NOTCH1 | 1.62 | 0 | 0.05 | 0.78359 | miRNATAP | -0.1 | 0.01874 | NA | |
119 | hsa-miR-92a-3p | NOTCH1 | 1.69 | 0 | 0.05 | 0.78359 | miRNATAP | -0.11 | 0.02256 | NA | |
120 | hsa-miR-92b-3p | NOTCH1 | 2.31 | 0 | 0.05 | 0.78359 | miRNATAP | -0.11 | 0.00018 | NA | |
121 | hsa-miR-103a-3p | NOTCH2 | 1.51 | 0 | -0.68 | 0 | MirTarget | -0.12 | 0.00227 | NA | |
122 | hsa-miR-107 | NOTCH2 | 1.81 | 0 | -0.68 | 0 | miRNAWalker2 validate; MirTarget; miRanda; miRNATAP | -0.16 | 1.0E-5 | NA | |
123 | hsa-miR-15a-5p | NOTCH2 | 1.78 | 0 | -0.68 | 0 | MirTarget | -0.17 | 4.0E-5 | NA | |
124 | hsa-miR-15b-5p | NOTCH2 | 2.5 | 0 | -0.68 | 0 | MirTarget | -0.15 | 2.0E-5 | NA | |
125 | hsa-miR-16-5p | NOTCH2 | 1.88 | 0 | -0.68 | 0 | miRNAWalker2 validate; MirTarget | -0.13 | 0.0014 | NA | |
126 | hsa-miR-185-5p | NOTCH2 | 1.98 | 0 | -0.68 | 0 | MirTarget | -0.12 | 0.00074 | NA | |
127 | hsa-miR-200b-5p | NOTCH2 | 4.84 | 0 | -0.68 | 0 | mirMAP | -0.11 | 0 | NA | |
128 | hsa-miR-330-5p | NOTCH2 | 2.22 | 0 | -0.68 | 0 | miRanda | -0.11 | 0.00046 | NA | |
129 | hsa-miR-340-5p | NOTCH2 | 1.35 | 0 | -0.68 | 0 | mirMAP | -0.15 | 0.00011 | NA | |
130 | hsa-miR-423-5p | NOTCH2 | 0.88 | 0 | -0.68 | 0 | MirTarget | -0.17 | 0.00011 | NA | |
131 | hsa-miR-744-5p | NOTCH2 | 1.84 | 0 | -0.68 | 0 | miRNAWalker2 validate | -0.11 | 0.00089 | NA | |
132 | hsa-miR-660-5p | NOTCH3 | 0.21 | 0.2672 | 0.66 | 0.00025 | MirTarget | -0.16 | 0.00062 | NA | |
133 | hsa-miR-125a-3p | NOTCH4 | 0.77 | 6.0E-5 | -1.02 | 0 | miRanda | -0.14 | 0.00013 | NA | |
134 | hsa-miR-146b-5p | NOTCH4 | 1.31 | 0 | -1.02 | 0 | miRanda | -0.19 | 0 | NA | |
135 | hsa-miR-18a-3p | NOTCH4 | 3.54 | 0 | -1.02 | 0 | miRNAWalker2 validate | -0.22 | 0 | NA | |
136 | hsa-miR-193a-3p | NOTCH4 | 0.42 | 0.05317 | -1.02 | 0 | miRanda | -0.1 | 0.00115 | NA | |
137 | hsa-miR-324-5p | NOTCH4 | 2.15 | 0 | -1.02 | 0 | miRanda | -0.23 | 0 | NA | |
138 | hsa-miR-330-5p | NOTCH4 | 2.22 | 0 | -1.02 | 0 | miRanda | -0.2 | 0 | NA | |
139 | hsa-miR-342-3p | NOTCH4 | 0.91 | 0 | -1.02 | 0 | miRanda | -0.15 | 0.00057 | NA | |
140 | hsa-miR-421 | NOTCH4 | 2.1 | 0 | -1.02 | 0 | miRanda | -0.16 | 0 | NA | |
141 | hsa-miR-429 | NOTCH4 | 5.04 | 0 | -1.02 | 0 | miRNATAP | -0.14 | 0 | NA | |
142 | hsa-miR-491-5p | NOTCH4 | 1.23 | 0 | -1.02 | 0 | miRanda | -0.16 | 0 | NA | |
143 | hsa-miR-103a-3p | NUMB | 1.51 | 0 | -0.16 | 0.07538 | miRNAWalker2 validate | -0.14 | 0 | NA | |
144 | hsa-miR-107 | NUMB | 1.81 | 0 | -0.16 | 0.07538 | miRanda | -0.1 | 1.0E-5 | NA | |
145 | hsa-miR-125a-3p | NUMB | 0.77 | 6.0E-5 | -0.16 | 0.07538 | miRanda | -0.12 | 0 | NA | |
146 | hsa-miR-146b-5p | NUMB | 1.31 | 0 | -0.16 | 0.07538 | PITA; miRanda; miRNATAP | -0.1 | 0 | NA | |
147 | hsa-miR-141-3p | NUMBL | 4.68 | 0 | -0.92 | 0 | TargetScan | -0.1 | 0 | NA | |
148 | hsa-miR-194-3p | NUMBL | 2.11 | 0 | -0.92 | 0 | MirTarget | -0.14 | 0 | NA | |
149 | hsa-miR-34a-5p | NUMBL | 0.94 | 1.0E-5 | -0.92 | 0 | MirTarget; miRNATAP | -0.12 | 0.00015 | NA | |
150 | hsa-let-7e-5p | RBPJ | 0.82 | 0 | -0.15 | 0.26186 | miRNATAP | -0.13 | 0.00678 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | NOTCH SIGNALING PATHWAY | 21 | 114 | 1.456e-41 | 6.776e-38 |
2 | REGULATION OF NOTCH SIGNALING PATHWAY | 11 | 67 | 1.307e-20 | 3.04e-17 |
3 | NOTCH RECEPTOR PROCESSING | 8 | 16 | 1.179e-19 | 1.828e-16 |
4 | POSITIVE REGULATION OF NOTCH SIGNALING PATHWAY | 9 | 34 | 5.204e-19 | 6.053e-16 |
5 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 16 | 750 | 1.164e-15 | 1.083e-12 |
6 | TRANSCRIPTION INITIATION FROM RNA POLYMERASE II PROMOTER | 10 | 153 | 1.343e-14 | 9.488e-12 |
7 | CELL FATE COMMITMENT | 11 | 227 | 1.427e-14 | 9.488e-12 |
8 | EPITHELIAL CELL FATE COMMITMENT | 6 | 15 | 3.315e-14 | 1.928e-11 |
9 | NEURON FATE COMMITMENT | 8 | 67 | 5.683e-14 | 2.938e-11 |
10 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 19 | 1672 | 6.726e-14 | 3.13e-11 |
11 | POSITIVE REGULATION OF GENE EXPRESSION | 19 | 1733 | 1.288e-13 | 5.449e-11 |
12 | DNA TEMPLATED TRANSCRIPTION INITIATION | 10 | 202 | 2.226e-13 | 8.631e-11 |
13 | EPITHELIUM DEVELOPMENT | 15 | 945 | 9.336e-13 | 3.342e-10 |
14 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 15 | 1004 | 2.232e-12 | 7.419e-10 |
15 | AUDITORY RECEPTOR CELL DIFFERENTIATION | 6 | 28 | 2.462e-12 | 7.637e-10 |
16 | REGULATION OF CELL DEVELOPMENT | 14 | 836 | 3.482e-12 | 1.013e-09 |
17 | ORGAN MORPHOGENESIS | 14 | 841 | 3.773e-12 | 1.033e-09 |
18 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 18 | 1805 | 4.371e-12 | 1.13e-09 |
19 | MORPHOGENESIS OF AN EPITHELIUM | 11 | 400 | 6.939e-12 | 1.699e-09 |
20 | EAR DEVELOPMENT | 9 | 195 | 7.931e-12 | 1.845e-09 |
21 | EMBRYO DEVELOPMENT | 14 | 894 | 8.575e-12 | 1.9e-09 |
22 | TUBE DEVELOPMENT | 12 | 552 | 9.545e-12 | 2.019e-09 |
23 | TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 13 | 724 | 1.118e-11 | 2.081e-09 |
24 | HAIR CELL DIFFERENTIATION | 6 | 35 | 1.053e-11 | 2.081e-09 |
25 | PATTERN SPECIFICATION PROCESS | 11 | 418 | 1.115e-11 | 2.081e-09 |
26 | HEART MORPHOGENESIS | 9 | 212 | 1.681e-11 | 3.009e-09 |
27 | NEUROGENESIS | 16 | 1402 | 1.776e-11 | 3.061e-09 |
28 | CELL SURFACE RECEPTOR SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT | 5 | 16 | 2.309e-11 | 3.837e-09 |
29 | CELL FATE DETERMINATION | 6 | 43 | 3.923e-11 | 6.295e-09 |
30 | REGULATION OF CELL DIFFERENTIATION | 16 | 1492 | 4.535e-11 | 7.034e-09 |
31 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 17 | 1784 | 5.16e-11 | 7.745e-09 |
32 | TISSUE DEVELOPMENT | 16 | 1518 | 5.878e-11 | 8.548e-09 |
33 | NEURONAL STEM CELL POPULATION MAINTENANCE | 5 | 19 | 6.127e-11 | 8.639e-09 |
34 | POSITIVE REGULATION OF CELL COMMUNICATION | 16 | 1532 | 6.746e-11 | 9.233e-09 |
35 | ARTERY MORPHOGENESIS | 6 | 51 | 1.149e-10 | 1.486e-08 |
36 | MECHANORECEPTOR DIFFERENTIATION | 6 | 51 | 1.149e-10 | 1.486e-08 |
37 | TISSUE MORPHOGENESIS | 11 | 533 | 1.501e-10 | 1.888e-08 |
38 | CARDIAC CHAMBER MORPHOGENESIS | 7 | 104 | 1.546e-10 | 1.893e-08 |
39 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 17 | 1929 | 1.778e-10 | 2.121e-08 |
40 | REGULATION OF NEURON DIFFERENTIATION | 11 | 554 | 2.263e-10 | 2.632e-08 |
41 | COLUMNAR CUBOIDAL EPITHELIAL CELL DIFFERENTIATION | 7 | 111 | 2.454e-10 | 2.785e-08 |
42 | NEGATIVE REGULATION OF NEURON DIFFERENTIATION | 8 | 191 | 2.921e-10 | 3.236e-08 |
43 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 13 | 957 | 3.567e-10 | 3.86e-08 |
44 | IMMUNE SYSTEM DEVELOPMENT | 11 | 582 | 3.815e-10 | 4.034e-08 |
45 | NEUROEPITHELIAL CELL DIFFERENTIATION | 6 | 63 | 4.283e-10 | 4.429e-08 |
46 | REGIONALIZATION | 9 | 311 | 5.087e-10 | 5.145e-08 |
47 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 12 | 788 | 5.794e-10 | 5.616e-08 |
48 | CIRCULATORY SYSTEM DEVELOPMENT | 12 | 788 | 5.794e-10 | 5.616e-08 |
49 | LYMPHOCYTE DIFFERENTIATION | 8 | 209 | 5.975e-10 | 5.673e-08 |
50 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 12 | 801 | 6.982e-10 | 6.479e-08 |
51 | TUBE MORPHOGENESIS | 9 | 323 | 7.101e-10 | 6.479e-08 |
52 | HEART DEVELOPMENT | 10 | 466 | 8.478e-10 | 7.443e-08 |
53 | MAINTENANCE OF CELL NUMBER | 7 | 132 | 8.336e-10 | 7.443e-08 |
54 | LYMPHOCYTE ACTIVATION | 9 | 342 | 1.174e-09 | 1.011e-07 |
55 | ARTERY DEVELOPMENT | 6 | 75 | 1.254e-09 | 1.061e-07 |
56 | EPIDERMAL CELL DIFFERENTIATION | 7 | 142 | 1.392e-09 | 1.157e-07 |
57 | SENSORY ORGAN DEVELOPMENT | 10 | 493 | 1.46e-09 | 1.192e-07 |
58 | CARDIAC CHAMBER DEVELOPMENT | 7 | 144 | 1.535e-09 | 1.211e-07 |
59 | EPITHELIAL CELL DIFFERENTIATION | 10 | 495 | 1.518e-09 | 1.211e-07 |
60 | NEURON DIFFERENTIATION | 12 | 874 | 1.88e-09 | 1.458e-07 |
61 | REGULATION OF TIMING OF CELL DIFFERENTIATION | 4 | 12 | 2.019e-09 | 1.515e-07 |
62 | REGULATION OF DEVELOPMENT HETEROCHRONIC | 4 | 12 | 2.019e-09 | 1.515e-07 |
63 | EPIDERMIS DEVELOPMENT | 8 | 253 | 2.702e-09 | 1.995e-07 |
64 | MATURE B CELL DIFFERENTIATION INVOLVED IN IMMUNE RESPONSE | 4 | 13 | 2.913e-09 | 2.118e-07 |
65 | NEGATIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 8 | 262 | 3.555e-09 | 2.44e-07 |
66 | B CELL DIFFERENTIATION | 6 | 89 | 3.566e-09 | 2.44e-07 |
67 | SEGMENTATION | 6 | 89 | 3.566e-09 | 2.44e-07 |
68 | EMBRYONIC MORPHOGENESIS | 10 | 539 | 3.441e-09 | 2.44e-07 |
69 | ENDOTHELIUM DEVELOPMENT | 6 | 90 | 3.817e-09 | 2.574e-07 |
70 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 10 | 554 | 4.475e-09 | 2.975e-07 |
71 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 11 | 740 | 4.746e-09 | 3.11e-07 |
72 | LEUKOCYTE ACTIVATION | 9 | 414 | 6.23e-09 | 4.026e-07 |
73 | LEUKOCYTE DIFFERENTIATION | 8 | 292 | 8.309e-09 | 5.296e-07 |
74 | MATURE B CELL DIFFERENTIATION | 4 | 17 | 9.655e-09 | 6.042e-07 |
75 | CARDIAC SEPTUM MORPHOGENESIS | 5 | 49 | 9.738e-09 | 6.042e-07 |
76 | NEGATIVE REGULATION OF CELL DEVELOPMENT | 8 | 303 | 1.109e-08 | 6.614e-07 |
77 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 12 | 1021 | 1.081e-08 | 6.614e-07 |
78 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 10 | 609 | 1.104e-08 | 6.614e-07 |
79 | REGULATION OF EMBRYONIC DEVELOPMENT | 6 | 114 | 1.595e-08 | 9.395e-07 |
80 | NEPHRON DEVELOPMENT | 6 | 115 | 1.681e-08 | 9.778e-07 |
81 | OUTFLOW TRACT MORPHOGENESIS | 5 | 56 | 1.937e-08 | 1.112e-06 |
82 | REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 6 | 122 | 2.398e-08 | 1.361e-06 |
83 | AORTA MORPHOGENESIS | 4 | 22 | 2.952e-08 | 1.655e-06 |
84 | B CELL ACTIVATION | 6 | 132 | 3.844e-08 | 2.129e-06 |
85 | BLOOD VESSEL MORPHOGENESIS | 8 | 364 | 4.6e-08 | 2.518e-06 |
86 | ENDOTHELIAL CELL DIFFERENTIATION | 5 | 72 | 6.976e-08 | 3.774e-06 |
87 | REGULATION OF CELL PROLIFERATION | 13 | 1496 | 7.807e-08 | 4.176e-06 |
88 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 11 | 983 | 8.825e-08 | 4.666e-06 |
89 | CELL ACTIVATION | 9 | 568 | 9.475e-08 | 4.92e-06 |
90 | REGULATION OF OLIGODENDROCYTE DIFFERENTIATION | 4 | 29 | 9.516e-08 | 4.92e-06 |
91 | RENAL TUBULE DEVELOPMENT | 5 | 78 | 1.046e-07 | 5.348e-06 |
92 | POSITIVE REGULATION OF BMP SIGNALING PATHWAY | 4 | 32 | 1.436e-07 | 7.186e-06 |
93 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO HYPOXIA | 4 | 32 | 1.436e-07 | 7.186e-06 |
94 | CARDIAC SEPTUM DEVELOPMENT | 5 | 85 | 1.613e-07 | 7.986e-06 |
95 | POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 8 | 437 | 1.871e-07 | 9.073e-06 |
96 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 10 | 823 | 1.872e-07 | 9.073e-06 |
97 | ANGIOGENESIS | 7 | 293 | 2.056e-07 | 9.864e-06 |
98 | B CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 4 | 35 | 2.085e-07 | 9.898e-06 |
99 | UROGENITAL SYSTEM DEVELOPMENT | 7 | 299 | 2.359e-07 | 1.109e-05 |
100 | NEPHRON EPITHELIUM DEVELOPMENT | 5 | 93 | 2.535e-07 | 1.18e-05 |
101 | NEGATIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 4 | 37 | 2.624e-07 | 1.209e-05 |
102 | IMMUNE SYSTEM PROCESS | 14 | 1984 | 2.676e-07 | 1.221e-05 |
103 | VASCULATURE DEVELOPMENT | 8 | 469 | 3.204e-07 | 1.447e-05 |
104 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 12 | 1395 | 3.358e-07 | 1.49e-05 |
105 | POSITIVE REGULATION OF CELL DEVELOPMENT | 8 | 472 | 3.363e-07 | 1.49e-05 |
106 | POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 5 | 100 | 3.646e-07 | 1.6e-05 |
107 | ANTERIOR POSTERIOR PATTERN SPECIFICATION | 6 | 194 | 3.771e-07 | 1.64e-05 |
108 | AORTA DEVELOPMENT | 4 | 41 | 4.007e-07 | 1.71e-05 |
109 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 11 | 1142 | 4.005e-07 | 1.71e-05 |
110 | CELL DEVELOPMENT | 12 | 1426 | 4.258e-07 | 1.801e-05 |
111 | NEGATIVE REGULATION OF STEM CELL DIFFERENTIATION | 4 | 43 | 4.873e-07 | 2.008e-05 |
112 | MORPHOGENESIS OF AN EPITHELIAL SHEET | 4 | 43 | 4.873e-07 | 2.008e-05 |
113 | CARDIAC VENTRICLE DEVELOPMENT | 5 | 106 | 4.877e-07 | 2.008e-05 |
114 | LOOP OF HENLE DEVELOPMENT | 3 | 11 | 4.984e-07 | 2.017e-05 |
115 | VENTRICULAR TRABECULA MYOCARDIUM MORPHOGENESIS | 3 | 11 | 4.984e-07 | 2.017e-05 |
116 | REGULATION OF EPIDERMAL CELL DIFFERENTIATION | 4 | 45 | 5.871e-07 | 2.355e-05 |
117 | REGULATION OF STEM CELL DIFFERENTIATION | 5 | 113 | 6.705e-07 | 2.667e-05 |
118 | FOREBRAIN DEVELOPMENT | 7 | 357 | 7.783e-07 | 3.069e-05 |
119 | GLOMERULUS DEVELOPMENT | 4 | 49 | 8.314e-07 | 3.251e-05 |
120 | NEGATIVE REGULATION OF OLIGODENDROCYTE DIFFERENTIATION | 3 | 13 | 8.622e-07 | 3.316e-05 |
121 | NEGATIVE REGULATION OF EPIDERMAL CELL DIFFERENTIATION | 3 | 13 | 8.622e-07 | 3.316e-05 |
122 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 6 | 229 | 9.958e-07 | 3.798e-05 |
123 | KIDNEY EPITHELIUM DEVELOPMENT | 5 | 125 | 1.106e-06 | 4.185e-05 |
124 | POSITIVE REGULATION OF BINDING | 5 | 127 | 1.197e-06 | 4.491e-05 |
125 | NEGATIVE REGULATION OF HEMOPOIESIS | 5 | 128 | 1.244e-06 | 4.631e-05 |
126 | N TERMINAL PROTEIN AMINO ACID ACETYLATION | 3 | 15 | 1.369e-06 | 4.992e-05 |
127 | REGULATION OF CELL PROLIFERATION INVOLVED IN HEART MORPHOGENESIS | 3 | 15 | 1.369e-06 | 4.992e-05 |
128 | REGULATION OF ORGAN MORPHOGENESIS | 6 | 242 | 1.373e-06 | 4.992e-05 |
129 | MORPHOGENESIS OF AN ENDOTHELIUM | 3 | 16 | 1.683e-06 | 5.978e-05 |
130 | NEGATIVE REGULATION OF EPIDERMIS DEVELOPMENT | 3 | 16 | 1.683e-06 | 5.978e-05 |
131 | GLIAL CELL DIFFERENTIATION | 5 | 136 | 1.679e-06 | 5.978e-05 |
132 | REGULATION OF GLIAL CELL DIFFERENTIATION | 4 | 59 | 1.767e-06 | 6.23e-05 |
133 | SEGMENT SPECIFICATION | 3 | 17 | 2.042e-06 | 7.143e-05 |
134 | SOMITOGENESIS | 4 | 62 | 2.159e-06 | 7.443e-05 |
135 | CARDIAC VENTRICLE MORPHOGENESIS | 4 | 62 | 2.159e-06 | 7.443e-05 |
136 | REGULATION OF EPIDERMIS DEVELOPMENT | 4 | 63 | 2.303e-06 | 7.881e-05 |
137 | NEURAL TUBE DEVELOPMENT | 5 | 149 | 2.631e-06 | 8.936e-05 |
138 | FOREBRAIN GENERATION OF NEURONS | 4 | 66 | 2.778e-06 | 9.301e-05 |
139 | MUSCLE STRUCTURE DEVELOPMENT | 7 | 432 | 2.768e-06 | 9.301e-05 |
140 | KIDNEY VASCULATURE DEVELOPMENT | 3 | 19 | 2.904e-06 | 9.582e-05 |
141 | RENAL SYSTEM VASCULATURE DEVELOPMENT | 3 | 19 | 2.904e-06 | 9.582e-05 |
142 | REGULATION OF DNA TEMPLATED TRANSCRIPTION IN RESPONSE TO STRESS | 4 | 67 | 2.952e-06 | 9.672e-05 |
143 | REGULATION OF BINDING | 6 | 283 | 3.397e-06 | 0.0001104 |
144 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 9 | 872 | 3.418e-06 | 0.0001104 |
145 | SKIN EPIDERMIS DEVELOPMENT | 4 | 71 | 3.726e-06 | 0.0001196 |
146 | POSITIVE REGULATION OF STAT CASCADE | 4 | 73 | 4.165e-06 | 0.0001319 |
147 | POSITIVE REGULATION OF JAK STAT CASCADE | 4 | 73 | 4.165e-06 | 0.0001319 |
148 | SOMATIC STEM CELL DIVISION | 3 | 22 | 4.601e-06 | 0.0001446 |
149 | REGULATION OF BMP SIGNALING PATHWAY | 4 | 77 | 5.158e-06 | 0.0001611 |
150 | SOMITE DEVELOPMENT | 4 | 78 | 5.431e-06 | 0.0001685 |
151 | NEGATIVE REGULATION OF GENE EXPRESSION | 11 | 1493 | 5.595e-06 | 0.0001724 |
152 | GLIOGENESIS | 5 | 175 | 5.781e-06 | 0.000177 |
153 | NEGATIVE REGULATION OF HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION | 3 | 24 | 6.034e-06 | 0.0001835 |
154 | REGULATION OF HEMOPOIESIS | 6 | 314 | 6.171e-06 | 0.0001864 |
155 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 11 | 1517 | 6.525e-06 | 0.0001959 |
156 | HEAD DEVELOPMENT | 8 | 709 | 7.02e-06 | 0.0002094 |
157 | HEART TRABECULA MORPHOGENESIS | 3 | 26 | 7.736e-06 | 0.0002264 |
158 | NEGATIVE REGULATION OF GLIAL CELL DIFFERENTIATION | 3 | 26 | 7.736e-06 | 0.0002264 |
159 | N TERMINAL PROTEIN AMINO ACID MODIFICATION | 3 | 26 | 7.736e-06 | 0.0002264 |
160 | TISSUE REMODELING | 4 | 87 | 8.395e-06 | 0.0002442 |
161 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 7 | 513 | 8.552e-06 | 0.0002472 |
162 | REGULATION OF ASTROCYTE DIFFERENTIATION | 3 | 27 | 8.694e-06 | 0.0002482 |
163 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER INVOLVED IN CELLULAR RESPONSE TO CHEMICAL STIMULUS | 3 | 27 | 8.694e-06 | 0.0002482 |
164 | REGULATION OF GLIOGENESIS | 4 | 90 | 9.607e-06 | 0.0002726 |
165 | NEGATIVE REGULATION OF NOTCH SIGNALING PATHWAY | 3 | 28 | 9.727e-06 | 0.0002727 |
166 | REGULATION OF SPROUTING ANGIOGENESIS | 3 | 28 | 9.727e-06 | 0.0002727 |
167 | RESPIRATORY SYSTEM DEVELOPMENT | 5 | 197 | 1.028e-05 | 0.0002864 |
168 | STEM CELL DIVISION | 3 | 29 | 1.084e-05 | 0.0002984 |
169 | REGULATION OF HEART MORPHOGENESIS | 3 | 29 | 1.084e-05 | 0.0002984 |
170 | CARDIOCYTE DIFFERENTIATION | 4 | 96 | 1.241e-05 | 0.0003397 |
171 | REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 5 | 207 | 1.306e-05 | 0.0003555 |
172 | CARDIAC ATRIUM DEVELOPMENT | 3 | 31 | 1.331e-05 | 0.00036 |
173 | LYMPHOCYTE ACTIVATION INVOLVED IN IMMUNE RESPONSE | 4 | 98 | 1.347e-05 | 0.0003623 |
174 | SKIN DEVELOPMENT | 5 | 211 | 1.433e-05 | 0.0003832 |
175 | ENDOCARDIAL CUSHION DEVELOPMENT | 3 | 32 | 1.467e-05 | 0.0003856 |
176 | POSITIVE REGULATION OF GLIAL CELL DIFFERENTIATION | 3 | 32 | 1.467e-05 | 0.0003856 |
177 | BLOOD VESSEL REMODELING | 3 | 32 | 1.467e-05 | 0.0003856 |
178 | HEART VALVE DEVELOPMENT | 3 | 34 | 1.766e-05 | 0.0004617 |
179 | POSITIVE REGULATION OF CELL PROLIFERATION | 8 | 814 | 1.917e-05 | 0.0004984 |
180 | CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT | 3 | 36 | 2.103e-05 | 0.0005436 |
181 | NEGATIVE REGULATION OF GLIOGENESIS | 3 | 37 | 2.286e-05 | 0.0005813 |
182 | MYOBLAST DIFFERENTIATION | 3 | 37 | 2.286e-05 | 0.0005813 |
183 | POSITIVE REGULATION OF TYROSINE PHOSPHORYLATION OF STAT3 PROTEIN | 3 | 37 | 2.286e-05 | 0.0005813 |
184 | SENSORY ORGAN MORPHOGENESIS | 5 | 239 | 2.609e-05 | 0.0006598 |
185 | POSITIVE REGULATION OF VIRAL TRANSCRIPTION | 3 | 39 | 2.684e-05 | 0.0006607 |
186 | TRABECULA MORPHOGENESIS | 3 | 39 | 2.684e-05 | 0.0006607 |
187 | ASTROCYTE DIFFERENTIATION | 3 | 39 | 2.684e-05 | 0.0006607 |
188 | COCHLEA DEVELOPMENT | 3 | 39 | 2.684e-05 | 0.0006607 |
189 | EMBRYONIC ORGAN DEVELOPMENT | 6 | 406 | 2.65e-05 | 0.0006607 |
190 | REGULATION OF HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION | 3 | 41 | 3.124e-05 | 0.000765 |
191 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 8 | 876 | 3.249e-05 | 0.0007915 |
192 | NEGATIVE REGULATION OF CELL PROLIFERATION | 7 | 643 | 3.669e-05 | 0.0008892 |
193 | REGULATION OF TYROSINE PHOSPHORYLATION OF STAT3 PROTEIN | 3 | 44 | 3.869e-05 | 0.0009329 |
194 | TUBE FORMATION | 4 | 129 | 3.975e-05 | 0.0009534 |
195 | VENTRICULAR CARDIAC MUSCLE TISSUE DEVELOPMENT | 3 | 45 | 4.142e-05 | 0.0009882 |
196 | MORPHOGENESIS OF EMBRYONIC EPITHELIUM | 4 | 134 | 4.612e-05 | 0.001089 |
197 | MESENCHYMAL CELL DIFFERENTIATION | 4 | 134 | 4.612e-05 | 0.001089 |
198 | POSITIVE REGULATION OF GLIOGENESIS | 3 | 47 | 4.723e-05 | 0.00111 |
199 | MUSCLE TISSUE DEVELOPMENT | 5 | 275 | 5.096e-05 | 0.001192 |
200 | MUSCLE ORGAN DEVELOPMENT | 5 | 277 | 5.275e-05 | 0.001227 |
201 | CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 4 | 139 | 5.321e-05 | 0.001232 |
202 | EMBRYONIC ORGAN MORPHOGENESIS | 5 | 279 | 5.458e-05 | 0.001257 |
203 | CELLULAR RESPONSE TO OXYGEN LEVELS | 4 | 143 | 5.943e-05 | 0.001362 |
204 | REGULATION OF JAK STAT CASCADE | 4 | 144 | 6.106e-05 | 0.001386 |
205 | REGULATION OF STAT CASCADE | 4 | 144 | 6.106e-05 | 0.001386 |
206 | CARDIAC MUSCLE TISSUE MORPHOGENESIS | 3 | 54 | 7.174e-05 | 0.00162 |
207 | RHYTHMIC PROCESS | 5 | 298 | 7.455e-05 | 0.001676 |
208 | REGULATION OF MUSCLE CELL DIFFERENTIATION | 4 | 152 | 7.535e-05 | 0.001685 |
209 | POSITIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT | 3 | 56 | 8.001e-05 | 0.001781 |
210 | POSITIVE REGULATION OF DEVELOPMENTAL GROWTH | 4 | 156 | 8.333e-05 | 0.001846 |
211 | RESPONSE TO OXYGEN LEVELS | 5 | 311 | 9.118e-05 | 0.002011 |
212 | POSITIVE REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION | 4 | 162 | 9.645e-05 | 0.002107 |
213 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 4 | 162 | 9.645e-05 | 0.002107 |
214 | EMBRYONIC DIGIT MORPHOGENESIS | 3 | 61 | 0.0001034 | 0.002237 |
215 | REGULATION OF VIRAL TRANSCRIPTION | 3 | 61 | 0.0001034 | 0.002237 |
216 | EMBRYONIC HEART TUBE MORPHOGENESIS | 3 | 62 | 0.0001085 | 0.002337 |
217 | ENDOCARDIUM DEVELOPMENT | 2 | 11 | 0.0001186 | 0.002498 |
218 | NEGATIVE REGULATION OF SPROUTING ANGIOGENESIS | 2 | 11 | 0.0001186 | 0.002498 |
219 | NEGATIVE REGULATION OF GLIAL CELL PROLIFERATION | 2 | 11 | 0.0001186 | 0.002498 |
220 | EPITHELIAL TO MESENCHYMAL TRANSITION INVOLVED IN ENDOCARDIAL CUSHION FORMATION | 2 | 11 | 0.0001186 | 0.002498 |
221 | ENDOTHELIAL TUBE MORPHOGENESIS | 2 | 11 | 0.0001186 | 0.002498 |
222 | REGULATION OF PROTEIN ACETYLATION | 3 | 64 | 0.0001193 | 0.0025 |
223 | CELLULAR RESPONSE TO RETINOIC ACID | 3 | 65 | 0.0001249 | 0.002607 |
224 | CARDIAC LEFT VENTRICLE MORPHOGENESIS | 2 | 12 | 0.0001422 | 0.00289 |
225 | POSITIVE REGULATION BY HOST OF VIRAL TRANSCRIPTION | 2 | 12 | 0.0001422 | 0.00289 |
226 | AMYLOID PRECURSOR PROTEIN METABOLIC PROCESS | 2 | 12 | 0.0001422 | 0.00289 |
227 | DISTAL TUBULE DEVELOPMENT | 2 | 12 | 0.0001422 | 0.00289 |
228 | LATERAL VENTRICLE DEVELOPMENT | 2 | 12 | 0.0001422 | 0.00289 |
229 | POSITIVE REGULATION OF ASTROCYTE DIFFERENTIATION | 2 | 12 | 0.0001422 | 0.00289 |
230 | REGULATION OF TYROSINE PHOSPHORYLATION OF STAT PROTEIN | 3 | 68 | 0.0001429 | 0.002891 |
231 | COVALENT CHROMATIN MODIFICATION | 5 | 345 | 0.0001483 | 0.002987 |
232 | MUSCLE ORGAN MORPHOGENESIS | 3 | 70 | 0.0001558 | 0.003124 |
233 | CELL FATE SPECIFICATION | 3 | 71 | 0.0001625 | 0.003245 |
234 | EPITHELIAL CELL DEVELOPMENT | 4 | 186 | 0.0001643 | 0.003266 |
235 | NEURONAL STEM CELL DIVISION | 2 | 13 | 0.0001679 | 0.003269 |
236 | VASCULAR SMOOTH MUSCLE CELL DIFFERENTIATION | 2 | 13 | 0.0001679 | 0.003269 |
237 | LEFT RIGHT AXIS SPECIFICATION | 2 | 13 | 0.0001679 | 0.003269 |
238 | CARDIOBLAST DIFFERENTIATION | 2 | 13 | 0.0001679 | 0.003269 |
239 | NEUROBLAST DIVISION | 2 | 13 | 0.0001679 | 0.003269 |
240 | POSITIVE REGULATION OF PROTEIN BINDING | 3 | 73 | 0.0001765 | 0.003407 |
241 | EMBRYONIC HEART TUBE DEVELOPMENT | 3 | 73 | 0.0001765 | 0.003407 |
242 | MESENCHYME DEVELOPMENT | 4 | 190 | 0.0001782 | 0.003413 |
243 | STEM CELL DIFFERENTIATION | 4 | 190 | 0.0001782 | 0.003413 |
244 | REGULATION OF ESTABLISHMENT OF PLANAR POLARITY INVOLVED IN NEURAL TUBE CLOSURE | 2 | 14 | 0.0001957 | 0.003733 |
245 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 8 | 1135 | 0.0002001 | 0.0038 |
246 | NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 5 | 372 | 0.0002106 | 0.003983 |
247 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 8 | 1152 | 0.0002216 | 0.004175 |
248 | RESPONSE TO MURAMYL DIPEPTIDE | 2 | 15 | 0.0002256 | 0.004216 |
249 | ENDOCARDIAL CUSHION FORMATION | 2 | 15 | 0.0002256 | 0.004216 |
250 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 9 | 1492 | 0.0002372 | 0.004414 |
251 | METANEPHROS DEVELOPMENT | 3 | 81 | 0.0002401 | 0.004451 |
252 | HAIR CYCLE | 3 | 83 | 0.0002581 | 0.004709 |
253 | CARDIAC RIGHT VENTRICLE MORPHOGENESIS | 2 | 16 | 0.0002576 | 0.004709 |
254 | MOLTING CYCLE | 3 | 83 | 0.0002581 | 0.004709 |
255 | APOPTOTIC PROCESS INVOLVED IN MORPHOGENESIS | 2 | 16 | 0.0002576 | 0.004709 |
256 | REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION | 3 | 85 | 0.0002768 | 0.004992 |
257 | REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION | 4 | 213 | 0.0002758 | 0.004992 |
258 | POSITIVE REGULATION OF CHROMATIN MODIFICATION | 3 | 85 | 0.0002768 | 0.004992 |
259 | GLAND DEVELOPMENT | 5 | 395 | 0.0002779 | 0.004992 |
260 | MEMBRANE PROTEIN INTRACELLULAR DOMAIN PROTEOLYSIS | 2 | 17 | 0.0002917 | 0.00522 |
261 | CELLULAR COMPONENT MORPHOGENESIS | 7 | 900 | 0.0002993 | 0.005336 |
262 | LABYRINTHINE LAYER BLOOD VESSEL DEVELOPMENT | 2 | 18 | 0.0003279 | 0.0058 |
263 | PERICARDIUM DEVELOPMENT | 2 | 18 | 0.0003279 | 0.0058 |
264 | POSITIVE REGULATION OF VIRAL PROCESS | 3 | 92 | 0.0003495 | 0.00616 |
265 | TELENCEPHALON DEVELOPMENT | 4 | 228 | 0.0003572 | 0.006271 |
266 | REGULATION OF DNA BINDING | 3 | 93 | 0.0003608 | 0.006311 |
267 | REGULATION OF CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 2 | 19 | 0.0003661 | 0.006356 |
268 | POSITIVE REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION | 2 | 19 | 0.0003661 | 0.006356 |
269 | REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 4 | 236 | 0.000407 | 0.007013 |
270 | METANEPHRIC EPITHELIUM DEVELOPMENT | 2 | 20 | 0.0004064 | 0.007013 |
271 | MUSCLE CELL DIFFERENTIATION | 4 | 237 | 0.0004135 | 0.0071 |
272 | CELL PROLIFERATION | 6 | 672 | 0.0004192 | 0.007161 |
273 | POSITIVE REGULATION OF GROWTH | 4 | 238 | 0.0004202 | 0.007161 |
274 | METANEPHRIC NEPHRON MORPHOGENESIS | 2 | 21 | 0.0004487 | 0.007484 |
275 | INNER EAR RECEPTOR STEREOCILIUM ORGANIZATION | 2 | 21 | 0.0004487 | 0.007484 |
276 | LEFT RIGHT PATTERN FORMATION | 2 | 21 | 0.0004487 | 0.007484 |
277 | REGULATION OF GLIAL CELL PROLIFERATION | 2 | 21 | 0.0004487 | 0.007484 |
278 | APOPTOTIC PROCESS INVOLVED IN DEVELOPMENT | 2 | 21 | 0.0004487 | 0.007484 |
279 | COCHLEA MORPHOGENESIS | 2 | 21 | 0.0004487 | 0.007484 |
280 | KERATINOCYTE DIFFERENTIATION | 3 | 101 | 0.0004596 | 0.007638 |
281 | NEURON DEVELOPMENT | 6 | 687 | 0.0004714 | 0.007805 |
282 | ENDOCARDIAL CUSHION MORPHOGENESIS | 2 | 22 | 0.0004932 | 0.007995 |
283 | REGULATION OF MUSCLE TISSUE DEVELOPMENT | 3 | 103 | 0.0004868 | 0.007995 |
284 | BETA CATENIN DESTRUCTION COMPLEX DISASSEMBLY | 2 | 22 | 0.0004932 | 0.007995 |
285 | MODULATION OF TRANSCRIPTION IN OTHER ORGANISM INVOLVED IN SYMBIOTIC INTERACTION | 2 | 22 | 0.0004932 | 0.007995 |
286 | MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS | 2 | 22 | 0.0004932 | 0.007995 |
287 | REGULATION OF MUSCLE ORGAN DEVELOPMENT | 3 | 103 | 0.0004868 | 0.007995 |
288 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 9 | 1656 | 0.0005159 | 0.008335 |
289 | SPINAL CORD DEVELOPMENT | 3 | 106 | 0.0005294 | 0.008523 |
290 | ESTABLISHMENT OF EPITHELIAL CELL POLARITY | 2 | 23 | 0.0005396 | 0.00857 |
291 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL METABOLIC PROCESS | 2 | 23 | 0.0005396 | 0.00857 |
292 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO STRESS | 2 | 23 | 0.0005396 | 0.00857 |
293 | POSITIVE REGULATION OF COLLAGEN METABOLIC PROCESS | 2 | 23 | 0.0005396 | 0.00857 |
294 | LEUKOCYTE CELL CELL ADHESION | 4 | 255 | 0.0005449 | 0.008595 |
295 | RESPONSE TO RETINOIC ACID | 3 | 107 | 0.0005441 | 0.008595 |
296 | NEGATIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 2 | 24 | 0.0005881 | 0.009152 |
297 | NEGATIVE REGULATION OF MYOBLAST DIFFERENTIATION | 2 | 24 | 0.0005881 | 0.009152 |
298 | EPITHELIAL CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT | 2 | 24 | 0.0005881 | 0.009152 |
299 | CARDIAC EPITHELIAL TO MESENCHYMAL TRANSITION | 2 | 24 | 0.0005881 | 0.009152 |
300 | LUNG CELL DIFFERENTIATION | 2 | 25 | 0.0006387 | 0.009906 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | NOTCH BINDING | 8 | 18 | 4e-19 | 3.716e-16 |
2 | TRANSCRIPTION FACTOR BINDING | 10 | 524 | 2.625e-09 | 1.219e-06 |
3 | TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING | 10 | 588 | 7.904e-09 | 2.448e-06 |
4 | TRANSCRIPTION COACTIVATOR ACTIVITY | 7 | 296 | 2.203e-07 | 5.117e-05 |
5 | RECEPTOR BINDING | 12 | 1476 | 6.171e-07 | 0.0001147 |
6 | CHROMATIN BINDING | 7 | 435 | 2.897e-06 | 0.0004486 |
7 | CALCIUM ION BINDING | 8 | 697 | 6.194e-06 | 0.000822 |
8 | RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING | 4 | 104 | 1.704e-05 | 0.001979 |
9 | CORE PROMOTER BINDING | 4 | 152 | 7.535e-05 | 0.007777 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | CHROMATIN | 7 | 441 | 3.172e-06 | 0.001852 |
2 | NUCLEOPLASM PART | 8 | 708 | 6.948e-06 | 0.002029 |
3 | NUCLEAR CHROMATIN | 5 | 291 | 6.663e-05 | 0.009728 |
4 | GOLGI MEMBRANE | 7 | 703 | 6.461e-05 | 0.009728 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | Notch_signaling_pathway_hsa04330 | 30 | 48 | 1.846e-84 | 9.597e-83 | |
2 | Wnt_signaling_pathway_hsa04310 | 4 | 146 | 6.443e-05 | 0.001675 | |
3 | Cell_cycle_hsa04110 | 3 | 124 | 0.0008357 | 0.01449 | |
4 | Adherens_junction_hsa04520 | 2 | 72 | 0.005209 | 0.06771 | |
5 | TGF_beta_signaling_pathway_hsa04350 | 2 | 84 | 0.007025 | 0.07306 | |
6 | HIF_1_signaling_pathway_hsa04066 | 2 | 100 | 0.009829 | 0.08518 | |
7 | FoxO_signaling_pathway_hsa04068 | 2 | 132 | 0.01667 | 0.1052 | |
8 | Apelin_signaling_pathway_hsa04371 | 2 | 137 | 0.01788 | 0.1052 | |
9 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 2 | 139 | 0.01837 | 0.1052 | |
10 | mTOR_signaling_pathway_hsa04150 | 2 | 151 | 0.02145 | 0.1052 | |
11 | Hippo_signaling_pathway_hsa04390 | 2 | 154 | 0.02225 | 0.1052 | |
12 | Jak_STAT_signaling_pathway_hsa04630 | 2 | 162 | 0.02445 | 0.106 | |
13 | cAMP_signaling_pathway_hsa04024 | 2 | 198 | 0.03538 | 0.1415 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | HAND2-AS1 |
hsa-miR-103a-3p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-146b-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-301a-3p;hsa-miR-320b;hsa-miR-326;hsa-miR-330-5p;hsa-miR-486-5p;hsa-miR-576-5p;hsa-miR-589-5p | 14 | DLL1 | Sponge network | -3.916 | 0.01209 | -1.564 | 0 | 0.286 |